When it comes to cancer, there is no single winner: despite advances, some cancers are still poorly managed. Within the next 5 to 10 years, chemotherapy is expected to give way to biomarker-guided strategies (MRD) and targeted therapies, including cell therapies. In recent years, precision oncology has benefited from a growing number of regulatory approvals, reflecting its increasing clinical relevance.